These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 24935295)

  • 1. Effect of rapamycin on spleen size in longstanding renal transplant recipients.
    Araújo NC; Sampaio Gonçalves de Lucena SB; da Silveira Rioja S
    Transplant Proc; 2014 Jun; 46(5):1319-23. PubMed ID: 24935295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional hyposplenism in long-standing renal transplant recipients.
    Araújo NC; de Lucena SB; Rioja SD
    Transplant Proc; 2013 May; 45(4):1558-61. PubMed ID: 23726619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
    Castroagudín JF; Molina E; Romero R; Otero E; Tomé S; Varo E
    Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrarenal vascular resistance parameters in kidney transplant patients receiving calcineurin inhibitor-based or sirolimus-based regimens.
    Lee PC; Lee CY; Hu RH; Lo C; Tsai MK; Lee PH
    Nephrol Dial Transplant; 2010 May; 25(5):1675-80. PubMed ID: 20042398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients.
    Segundo DS; Ruiz JC; Izquierdo M; Fernández-Fresnedo G; Gómez-Alamillo C; Merino R; Benito MJ; Cacho E; Rodrigo E; Palomar R; López-Hoyos M; Arias M
    Transplantation; 2006 Aug; 82(4):550-7. PubMed ID: 16926600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with everolimus is associated with a procoagulant state.
    Baas MC; Gerdes VE; Ten Berge IJ; Heutinck KM; Florquin S; Meijers JC; Bemelman FJ
    Thromb Res; 2013 Aug; 132(2):307-11. PubMed ID: 23906938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of 4-year analysis of conversion from calcineurin inhibitors to mTOR inhibitors in renal transplant patients: single-center experience.
    Sert M; Celik A; Kural K; Ersan S; Ataca P; Atila K; Cavdar C; Sifil A; Bora S; Gulay H; Camsari T
    Ren Fail; 2011; 33(8):789-94. PubMed ID: 21787153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal function outcomes in kidney transplant recipients after conversion to everolimus-based immunosuppression regimen with CNI reduction or elimination.
    Cataneo-Dávila A; Zúñiga-Varga J; Correa-Rotter R; Alberú J
    Transplant Proc; 2009 Dec; 41(10):4138-46. PubMed ID: 20005355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of mTOR inhibitors in chronic heart transplant recipients with renal failure: calcineurin-inhibitors conversion or minimization?
    Gonzalez-Vilchez F; Vazquez de Prada JA; Paniagua MJ; Gomez-Bueno M; Arizon JM; Almenar L; Roig E; Delgado J; Lambert JL; Perez-Villa F; Sanz-Julve ML; Crespo-Leiro M; Segovia J; Lopez-Granados A; Martinez-Dolz L; Mirabet S; Escribano P; Diaz-Molina B; Farrero M; Blasco T
    Int J Cardiol; 2014 Jan; 171(1):15-23. PubMed ID: 24309084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcineurin inhibitor substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients.
    Potter BJ; Giannetti N; Edwardes MD; Cecere R; Cantarovich M
    Clin Transplant; 2007; 21(3):305-8. PubMed ID: 17488377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirolimus in cardiac transplantation: use as a primary immunosuppressant in calcineurin inhibitor-induced nephrotoxicity.
    Kushwaha SS; Khalpey Z; Frantz RP; Rodeheffer RJ; Clavell AL; Daly RC; McGregor CG; Edwards BS
    J Heart Lung Transplant; 2005 Dec; 24(12):2129-36. PubMed ID: 16364861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of chronic allograft dysfunction by switch over to rapamycin.
    Sundaram V; Abraham G; Fathima N; Sundaram V; Reddy YN; Mathew M; Sathiah V
    Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):37-42. PubMed ID: 20061690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.
    Holdaas H; Rostaing L; Serón D; Cole E; Chapman J; Fellstrøm B; Strom EH; Jardine A; Midtvedt K; Machein U; Ulbricht B; Karpov A; O'Connell PJ;
    Transplantation; 2011 Aug; 92(4):410-8. PubMed ID: 21697773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications of proteinuria in renal transplant recipients switching to rapamycin for chronic allograft dysfunction.
    Gutiérrez MJ; González E; Andrés A; Morales JM
    Transplant Proc; 2009; 41(6):2348-50. PubMed ID: 19715916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
    Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion to everolimus in liver transplant patients with renal dysfunction.
    Pérez T; Segovia R; Castro L; Roblero JP; Estela R
    Transplant Proc; 2011; 43(6):2307-10. PubMed ID: 21839260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR inhibitor monotherapy. A good treatment choice in renal transplantation?
    Franco-Esteve A; Tordera D; de la Sen ML; Jiménez L; Mas P; Muñoz C; Olivares J
    Nefrologia; 2012; 32(5):631-8. PubMed ID: 23013949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
    Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
    Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Howell-Jolly bodies and liver-spleen scanning for assessment of splenic filtrative function yields discordant results in renal transplant recipients.
    Araújo NC; Orlando MMC; Neves MB; Rioja SS; de Lucena SBG; Mandarim-de-Lacerda CA
    Medicine (Baltimore); 2017 Dec; 96(51):e9242. PubMed ID: 29390481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.